Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference
CAMBRIDGE, Mass., May 16, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019, at 2:00 p.m. PT (5:00 p.m. ET) at The Beverly Hilton, Beverly Hills, CA. A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.
About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-1 is an ongoing Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in approximately 220 patients with advanced solid tumors including patients refractory to anti-PD-1 therapy. Infinity intends to initiate MARIO-275, a global, randomized, combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer patients in 2Q19, as well as to initiate MARIO-3, the first IPI-549 combination study in front-line advanced cancer patients in 2H19. MARIO-3 will evaluate IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. With the addition of MARIO-275 and MARIO-3 to the ongoing MARIO-1 study, Infinity will be evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve and front-line settings in a total of ~500 patients. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
View original content:http://www.prnewswire.com/news-releases/infinity-pharmaceuticals-to-present-at-b-riley-fbr-institutional-investor-conference-300851343.html
SOURCE Infinity Pharmaceuticals, Inc.

Related Stories
-
Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference
PR Newswire 05/16 08:32 ET -
Infinity Pharmaceuticals misses by $0.08
SA Breaking News 05/07 16:11 ET -
Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results
PR Newswire 05/07 16:05 ET -
Infinity Announces the Date of Its First Quarter 2019 Financial Results Conference Call and Webcast
PR Newswire 04/30 08:32 ET -
Detailed Research: Economic Perspectives on KB Home, Fitbit, Adamas Pharmaceuticals, Ballard Power, Infinity Pharmaceuticals, and Credit Acceptance — What Drives Growth in Today's Competitive Landscape
Globe Newswire 04/03 07:55 ET -
Infinity Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference
PR Newswire 04/02 08:32 ET -
Infinity Pharmaceuticals Reports Narrower FY18 Loss, Beats on Revenue; Files for Mixed Shelf Offering
MT Newswires 03/14 14:52 ET -
Infinity to Start Mario-3, A Mid-Stage Multi-Arm Study Evaluating IPI-549
MT Newswires 03/14 11:06 ET -
Infinity Pharma files for $100M mixed shelf offering; shares down 6%
SA Breaking News 03/14 10:38 ET -
PLUG, TNXP among premarket gainers
SA Breaking News 03/14 09:27 ET